Navigation Links
UNC scientists discover potential strategy to improve cancer vaccines
Date:12/14/2010

CHAPEL HILL, N.C. The promise of vaccines targeted against various types of cancer has raised the hopes of patients and their families. The reality, however, is that these promising treatments are difficult to develop. One of the challenges is identifying a discrete cellular target to stop cancer growth without inactivating the immune system. Scientists at UNC Lineberger Comprehensive Cancer Center report a laboratory finding that has the potential to increase the effectiveness of therapeutic cancer vaccines.

The team found that the absence of the function of a protein called NLRP3 can result in a four-fold increase in a tumor's response to a therapeutic cancer vaccine. If this finding proves consistent, it may be a key to making cancer vaccines a realistic treatment option. Their findings were published in the Dec. 15, 2010 issue of the journal Cancer Research.

Jonathan Serody, MD, a study author, explains, "This finding suggests an unexpected role for NLRP3 in vaccine development and gives us a potentially pharmacologic target to increase vaccine efficacy."

The research team was headed by co-leaders of the UNC Lineberger Immunology Program: Serody, MD, an expert in tumor immunology, and Jenny Ting, PhD, a pioneer in understanding the NLR family of proteins. Serody is the Elizabeth Thomas Professor of Hematology and Oncology. Ting is UNC Alumni Distinguished Professor of Microbiology and Immunology and director of the Inflammation Center at UNC.

The team discovered that deleting the NLRP3 proteins reduced the supply of a tumor-associated cell called myeloid-derived suppressors, making them five times less effective in reaching the site of tumor growth. Researchers working with Serody had previously shown that these myeloid cells are critically important as they allow the tumor to evade a beneficial immune response. This finding is the first to link immature myeloid cells, NLRP3, and the response to cancer vaccines.

Serody says, "We had originally thought inactivating the NLRP3 protein would decrease the immune system's ability to respond to cancer because NLRP3 is important in alerting immune cells to changes in the environment the immune response to cancer. Instead what we found was that by inactivating these proteins, the tumor vaccine was made more effective because fewer myeloid-derived suppressor cells were available to promote tumor growth and reduce the efficacy of the vaccine."

At present, there is only one FDA-approved cancer vaccine called Provenge, used to treat advanced prostate cancer. Provenge has been shown to extend survival by three to four months.

Vaccines are difficult to make. Because a vaccine is person-specific, made with the individual's immune cells, the production process requires that the individual's cells are isolated and shipped to the company for vaccine production. As a result, the vaccines are expensive. Provenge costs approximately $100,000 for three treatments.

"A vaccine is not like a pill that can be manufactured in bulk," Serody explains. "And, it's not like developing a vaccine against a virus such as polio or smallpox. Cancer cells look a lot like regular cells, so it is hard to trick the body into thinking cancer cells are 'foreign.' Our hope is that our findings and future work in this area will enable us to develop more effective vaccines against many types of cancer. "


'/>"/>

Contact: Dianne Shaw
dgs@med.unc.edu
919-966-5905
University of North Carolina School of Medicine
Source:Eurekalert

Related medicine news :

1. Scientists Pinpoint Area of Brain That Fears Losing Money
2. Scientists Discover How HIV Is Transmitted Between Men
3. Prevention Is Key Research Goal for Premature Babies, Scientists Say
4. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
5. Scientists find donut-shaped structure of enzyme involved in energy metabolism
6. Neuroscientists reveal new links that regulate brain electrical activity
7. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. Scientists Spot Genetic Fingerprints of Individual Cancers
10. Scientists Unravel Mysteries of Intelligence
11. MSU scientists develop more effective method of predicting lead-poisoning risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Yisrayl Hawkins, ... focuses on Bible Prophecy concerning this present generation. Yisrayl makes an astounding statement ... current generation. He explains that the Bible details the current times so plainly ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... return to the La Gorce Country Club in Miami Beach to host its ...
(Date:2/23/2017)... Lawn, NJ (PRWEB) , ... February 23, 2017 ... ... specializing in thought leadership , media relations, content marketing, social media management, ... With several clients already in the state and in nearby New Hampshire, Massachusetts ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... -- Research and Markets has announced the addition of ... report to their offering. ... The latest research Urinary Incontinence Drugs Price Analysis ... the global Urinary Incontinence market. The research answers the following ... marketed for Urinary Incontinence and their clinical attributes? How are they ...
(Date:2/23/2017)... Feb. 23, 2017  Genesis Healthcare Services has merged ... was made by Bill Monast , President and ... and Nathan Feltman , executives with Home Health ... LLC. This acquisition helps Hospice Cloud ... technology enabled durable medical equipment (DME) solutions for the ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
Breaking Medicine Technology: